Theseus Pharmaceuticals IPO

Theseus Pharmaceuticals is committed to outsmarting cancer resistance by developing best-in-class, pan-variant kinase inhibitors, to shape the future of targeted oncology.

Register for Details

For more details on financing and valuation for Theseus Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Updated on: May 17, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.